Skip to main content

Carmen Pilar Simeón i Aznar

Institutions of which they are part

Main researcher
Systemic Diseases
Vall Hebron Institut de Recerca

Carmen Pilar Simeón i Aznar

Institutions of which they are part

Main researcher
Systemic Diseases
Vall Hebron Institut de Recerca

Research lines

Protein expression of small collagenase 3 and leucine-rich proteoglycans in cutaneous tissue of patients with diffuse scleroderma.

This study, carried out along with researchers from the Hospital del Mar and from the "Institut Municipal d'Investigació Mèdica", aims at correlating the expression of SLRPs and MMP-13 with the severity of cutaneous involvement, hand dysfunctional capacity, capillaroscopy patterns, and cutaneous ultrasonography of patients affected with diffuse scleroderma in different evolutive stages of the disease.

IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla

Evaluation and characterization of cardiac involvement in patients with Systemic Sclerosis.

Cardiac involvement is one of the most serious internal organ involvements and the leading cause of death in SSc patients. The prevalence is 14% by clinical observation and even higher by autopsy Many SSc patients with cardiac involvement are asymptomatic or underdiagnosed. The condition may progress silently to overt clinical manifestations, including systolic and/or diastolic dysfunction, myocardial ischaemia, myocardial hypertrophy, heart failure, pericardial effusion and arrhythmias. Early detection of cardiac abnormalities is therefore very important. We evaluate cardiac involvement by echocardiography, MR, SPECT, and coronary CT.

IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla

Specific Antinuclear antibodies of scleroderma as markers for different clinical patterns.

We want to establish the relationship between the presence of specific autoantibodies for scleroderma (anti-centromere, anti-topoisomerase 1, anti-polymerase III, anti-U3 RNP, Anti-Th/To, Anti-Pm/Scl, anti-Ku) with the different demographic and clinical features as well as with the disease prognosis.

IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla

Genetic basis of scleroderma.

With this study we aim at studying the genetic background of the disease to deepen in its pathogenesis to be able to establish links between genetic variations and different clinic-biologic patterns. This research is based on a multicentric study and it is led by Prof. Javier Martín from the "Instituto López-Neyra" of Parasitology, CSIC (Granada). We contribute to it by sending samples from our cohort of patients along with the clinical data.

IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla

Projects

EUSTAR PROJECT 2023

IP: Carmen Pilar Simeón i Aznar
Collaborators: -
Funding agency: European Scleroderma Trials and Research group
Funding: 20000
Reference: EUSTAR/GRANT/2023/SIMEON
Duration: 01/05/2024

Ajuts Grups de Recerca (SGR) 2022

IP: Jaume Alijotas Reig
Collaborators: Moisés Labrador Horrillo, Carmen Pilar Simeón i Aznar, Anna Sala Cunill, Roser Solans Laque, Segundo Bujan Rivas, Mar Guilarte Clavero, Vicenç Fonollosa Pla, Fernando Martínez Valle, Victòria Cardona Dahl, Francesc Miro Mur, Alfredo Guillen Del Castillo, Albert Selva O'Callaghan, José Pardos Gea, Ajuts Grups de Recerca (SGR) 2022, Ariadna Anunciacion Llunell
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00048
Duration: 01/01/2022 - 30/06/2025

Estudio de expresión de antígenos en tejido tumoral de pacientes con Esclerosis Sistémica.

IP: Alfredo Guillen Del Castillo
Collaborators: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla, Maria Roca Herrera, Janire Perurena Prieto, Irene Sansano Valero
Funding agency: Instituto de Salud Carlos III
Funding: 75020
Reference: PI22/01804
Duration: 01/01/2023 - 31/12/2025

Design of an integrative patients stratification approach for the systemic sclerosis management

IP: Carmen Pilar Simeón i Aznar
Collaborators: -
Funding agency: Fundació La Marató de TV3
Funding: 72250
Reference: 202022-30-31-32-33
Duration: 10/05/2021 - 31/12/2024

Related news

The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.

Related professionals

Maria Pinyol Sarrias

Maria Pinyol Sarrias

Junior researcher
Infection and immunity in pediatric patients
Read more
LUCIA RODRIGUEZ NEBOT

LUCIA RODRIGUEZ NEBOT

Tècnic/a Grau Superior
Clinical Trials Management Unit
Clinical Research Development Directorate
Read more
Adaia Albasanz Puig

Adaia Albasanz Puig

Postdoctoral researcher
Infectious Diseases
Read more
Eros Alejandro Marin Millan

Eros Alejandro Marin Millan

Postdoctoral researcher
Rheumatology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.